C2-substituted quinazolinone derivatives exhibit A

Adenosine A1 Receptor Antagonists / chemical synthesis Adenosine A2 Receptor Antagonists / chemical synthesis Animals Dose-Response Relationship, Drug Molecular Structure Quinazolinones / chemical synthesis Rats Receptor, Adenosine A1 / metabolism Receptor, Adenosine A2A / metabolism Structure-Activity Relationship
Adenosine A(1) receptor Adenosine A(2A) receptor Antagonist Benzo-α-pyrone Benzoxazinone GTP shift Parkinson's disease Quinazolinone Radioligand binding assay

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 08 2020
Historique:
received: 06 02 2020
revised: 11 05 2020
accepted: 16 05 2020
entrez: 8 7 2020
pubmed: 8 7 2020
medline: 29 5 2021
Statut: ppublish

Résumé

Antagonists of the adenosine receptors (A

Identifiants

DOI: 10.1016/j.bmcl.2020.127274 PMID: 32631506
pubmed: 32631506
pii: S0960-894X(20)30384-X
doi: 10.1016/j.bmcl.2020.127274
pii:
doi:

Substances chimiques

Adenosine A1 Receptor Antagonists 0
Adenosine A2 Receptor Antagonists 0
Quinazolinones 0
Receptor, Adenosine A1 0
Receptor, Adenosine A2A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

127274

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lianie Pieterse (L)

Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa.

Mietha M van der Walt (MM)

Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa; Human Metabolomics, Faculty of Natural and Agricultural Science, North-West University, Private Bag X6001, Box 269, Potchefstroom 2531, South Africa. Electronic address: 13035134@nwu.ac.za.

Gisella Terre'Blanche (G)

Centre of Excellence for Pharmaceutical Sciences, School of Pharmacy, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa; Pharmaceutical Chemistry, School of Pharmacy, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents purinergiques › Antagonistes purinergiques › Antagonistes des récepteurs purinergiques P1 › Antagonistes du récepteur A1 à l'adénosine › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents purinergiques › Antagonistes purinergiques › Antagonistes des récepteurs purinergiques P1 › Antagonistes des récepteurs A2 à l'adénosine › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Eucaryotes › Animaux › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinazolines › Quinazolinones › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P1 › Récepteur A1 à l'adénosine › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs purinergiques › Récepteurs purinergiques P1 › Récepteurs A2 à l'adénosine › Récepteur A2A à l'adénosine › C2-substituted quinazolinone derivatives exhibit A
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › C2-substituted quinazolinone derivatives exhibit A